Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
Centro de Investigación del Cáncer · Centro de Investigación Biomédica en Red de Cáncer · +39 more institutions
Abstract
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease.
In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of treatment. The primary outcome was progression-free survival.
Citation impact
- FWCI
- 150.46
- Percentile
- 100%
- References
- 27
Authors
43- JFJesús F. San MiguelCorresponding
Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, University College London, University of Pamplona
- BDBinod Dhakal
Medical College of Wisconsin, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, University College London
- KYKwee Yong
Cancer Institute (WIA), London Cancer, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, University College London
- ASAndrew Spencer
Australian Regenerative Medicine Institute, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, University College London, Monash University
- SASébastien Anguille
Antwerp University Hospital, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, University College London
Topics & keywords
- Lenalidomide
- Multiple myeloma
- Refractory (planetary science)
- Standard of care
- Medicine
- Internal medicine
- Oncology
- Biology
- Good health and well-being